Tender detail
Conclusion of a non-exclusive pharmaceutical discount agreement for indacaterol and glycopyrronium bromide (1 December 2026–30 November 2028)
Summary
DAK-Gesundheit intends to conclude pharmaceutical discount agreements with interested pharmaceutical companies for medicines containing the active ingredients indacaterol and glycopyrronium bromide (ATC R03AL04). The agreements are scheduled to take effect on 1 December 2026 and run until 30 November 2028, but will end earlier if an exclusive agreement for the active ingredient takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.